554 related articles for article (PubMed ID: 30736475)
61. Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer.
Dienstmann R; Salazar R; Tabernero J
Am Soc Clin Oncol Educ Book; 2018 May; 38():231-238. PubMed ID: 30231342
[TBL] [Abstract][Full Text] [Related]
62. Prognostic Biomarkers of Cell Proliferation in Colorectal Cancer (CRC): From Immunohistochemistry to Molecular Biology Techniques.
Kasprzak A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760539
[TBL] [Abstract][Full Text] [Related]
63. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
64. The evolving role of microsatellite instability in colorectal cancer: A review.
Gelsomino F; Barbolini M; Spallanzani A; Pugliese G; Cascinu S
Cancer Treat Rev; 2016 Dec; 51():19-26. PubMed ID: 27838401
[TBL] [Abstract][Full Text] [Related]
65. Methylator phenotype in colorectal cancer: A prognostic factor or not?
Gallois C; Laurent-Puig P; Taieb J
Crit Rev Oncol Hematol; 2016 Mar; 99():74-80. PubMed ID: 26702883
[TBL] [Abstract][Full Text] [Related]
66. First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
Moiseyenko VM; Moiseyenko FV; Yanus GA; Kuligina ES; Sokolenko AP; Bizin IV; Kudriavtsev AA; Aleksakhina SN; Volkov NM; Chubenko VA; Kozyreva KS; Kramchaninov MM; Zhuravlev AS; Shelekhova KV; Pashkov DV; Ivantsov AO; Venina AR; Sokolova TN; Preobrazhenskaya EV; Mitiushkina NV; Togo AV; Iyevleva AG; Imyanitov EN
Clin Drug Investig; 2018 Jun; 38(6):553-562. PubMed ID: 29470838
[TBL] [Abstract][Full Text] [Related]
67. Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Chu J; Fang X; Sun Z; Gai L; Dai W; Li H; Yan X; Du J; Zhang L; Zhao L; Xu D; Yan S
Front Oncol; 2021; 11():801319. PubMed ID: 35111681
[TBL] [Abstract][Full Text] [Related]
68. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer.
Martini G; Dienstmann R; Ros J; Baraibar I; Cuadra-Urteaga JL; Salva F; Ciardiello D; Mulet N; Argiles G; Tabernero J; Elez E
Ther Adv Med Oncol; 2020; 12():1758835920936089. PubMed ID: 32782486
[TBL] [Abstract][Full Text] [Related]
69. Molecular mechanisms and clinical implications of miRNAs in drug resistance of colorectal cancer.
Duan L; Yang W; Feng W; Cao L; Wang X; Niu L; Li Y; Zhou W; Zhang Y; Liu J; Zhang H; Zhao Q; Hong L; Fan D
Ther Adv Med Oncol; 2020; 12():1758835920947342. PubMed ID: 32922521
[TBL] [Abstract][Full Text] [Related]
70. Molecular Targets for the Treatment of Metastatic Colorectal Cancer.
Cohen R; Pudlarz T; Delattre JF; Colle R; André T
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825275
[TBL] [Abstract][Full Text] [Related]
71. Epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers.
Danese E; Montagnana M
Ann Transl Med; 2017 Jul; 5(13):279. PubMed ID: 28758105
[TBL] [Abstract][Full Text] [Related]
72. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies.
Clarke CN; Kopetz ES
J Gastrointest Oncol; 2015 Dec; 6(6):660-7. PubMed ID: 26697199
[TBL] [Abstract][Full Text] [Related]
73. Targeted therapies in colorectal cancer-an integrative view by PPPM.
Hagan S; Orr MC; Doyle B
EPMA J; 2013 Jan; 4(1):3. PubMed ID: 23356214
[TBL] [Abstract][Full Text] [Related]
74. Molecular testing to optimize therapeutic decision making in advanced colorectal cancer.
Semrad TJ; Kim EJ
J Gastrointest Oncol; 2016 Apr; 7(Suppl 1):S11-20. PubMed ID: 27034809
[TBL] [Abstract][Full Text] [Related]
75. Recent developments in the treatment of metastatic colorectal cancer.
Loree JM; Kopetz S
Ther Adv Med Oncol; 2017 Aug; 9(8):551-564. PubMed ID: 28794806
[TBL] [Abstract][Full Text] [Related]
76. Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies.
Kitsel Y; Cooke T; Sotirchos V; Sofocleous CT
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980565
[TBL] [Abstract][Full Text] [Related]
77. Colorectal Cancer: Personalized Therapy.
Leichsenring J; Koppelle A; Reinacher-Schick A
Gastrointest Tumors; 2014 May; 1(4):209-20. PubMed ID: 26676107
[TBL] [Abstract][Full Text] [Related]
78. Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer.
Koulis C; Yap R; Engel R; Jardé T; Wilkins S; Solon G; Shapiro JD; Abud H; McMurrick P
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32231042
[TBL] [Abstract][Full Text] [Related]
79. Biomarkers in the development of individualized treatment regimens for colorectal cancer.
Crutcher M; Waldman S
Front Med (Lausanne); 2022; 9():1062423. PubMed ID: 36530921
[TBL] [Abstract][Full Text] [Related]
80. Colorectal Cancer: From Genetic Landscape to Targeted Therapy.
El Bali M; Bakkach J; Bennani Mechita M
J Oncol; 2021; 2021():9918116. PubMed ID: 34326875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
